Close

Theraclone doses first patient in Phase 1 TCN-032 drug trial

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How To Select A CDMO: Focus On Client-Centered Approach

When it comes to the pharmaceutical sector, choosing the...

Navigating Pharma Market Growth: CDMO Strategies For 2025

By the year 2025, it is projected that the...

Revolutionary Drug Delivery System With Nanoparticle Tech

When Willus Fisher, a doctorate candidate at the University...

Revolutionizing Biologics : Inhalation And Liquid Delivery

It is noteworthy that the pharmaceutical industry is gradually...

Theraclone Sciences has dosed first patient in a randomized, double-blind, dose-escalation Phase 1 trial investigating TCN-032 as a treatment for influenza A virus.

TCN-032 was discovered utilizing Theraclone’s I-STAR platform.The trial aims to investigate the safety profile of a single intravenous administration of TCN-032 compared to placebo.The study expects to recruit aorund 40 volunteers at a single US site and will also provide pharmacokinetic and immunogenicity data.

Theraclone executive chairman and acting CEO Steven Gillis said I-STAR has repeatedly demonstrated an ability to identify natural human antibodies with exceptionally biologic activity and therapeutic potential.

Latest stories

Related stories

How To Select A CDMO: Focus On Client-Centered Approach

When it comes to the pharmaceutical sector, choosing the...

Navigating Pharma Market Growth: CDMO Strategies For 2025

By the year 2025, it is projected that the...

Revolutionary Drug Delivery System With Nanoparticle Tech

When Willus Fisher, a doctorate candidate at the University...

Revolutionizing Biologics : Inhalation And Liquid Delivery

It is noteworthy that the pharmaceutical industry is gradually...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back